

CURRENT STATUS OF EXPOSED MARSHALLESE

- | | | |
|-----|--|-----|
| I | Young Rongelapese, 0-10 years ATE. Dose: 175 rad + (600-1400) rem. | 19 |
| | a. Normal. | 2 |
| | b. Hyperthyroid + Thyroid therapy. | 3 |
| | c. Treated by Surgery (Nodularity). | 14 |
| | d. Adenomatous Goiter | |
| | e. Thyroid Cell Tumor | |
| | f. Malignant Papillary Adenoma | 1 |
| | g. Malignant Papillary Adenoma | 1 |
| II | Young Ailinginae, 0-10 years ATE. Normal. Dose: 69 rad. | 6 |
| III | Adult Rongelapese ATE. Dose: 175 rad + 160 rem. | 34 |
| | a. Papillary Carcinoma excised, age 41. | 1 |
| | b. Intensive Adenoma. | 1 |
| IV | Adult Ailinginae ATE. Dose: 69 rad. | 8 |
| V | Adult and Young Utrikese ATE. Dose: 8 rad. | 180 |
| | a. Malignant Follicular Adenoma excised. | 1 |
| VI | Control Populations - Rongerik, Utrik, Rongelap, Utrik. | 200 |
| | a. Adenoma Goiter. | |

THYROID DISEASE IN MARSHALLESE

<u>AGE AT EXAMINATION</u>	<u>THYROID DOSE (RADS)</u>	<u>THYROID NODULES</u>	<u>SURGERY</u>	<u>MALIGNANT</u>
ENTIRE				
1-17		33% (1/3)	1	0
18-49		0 (0/1)	0	0
50+ YEARS				
ADVERSELY AFFECTED	810-1150	89% (17/19)*	15	1
UNADVERSELY AFFECTED	100-100	13% (3/23)	1	0
VERA	80-10	25 (1/58)	0	0
COMARCONS	80-10	33% (1/94)	0	0
2-10 YEARS				
ADVERSELY AFFECTED	80-10	13% (5/41)	4	2
UNADVERSELY AFFECTED	100-10	33% (5/12)	3	0
VERA	80-10	25 (6/99)	4	1
COMARCONS	80-10	33% (3/39)	3	0

*ALL PATIENTS INCLUDED ON HYPOPHYSECTOMY WITHOUT NODULES